Eisai Co. Ltd.

ESAIY | OTC

Price Alert Chart Builder DCF Calculator

$7.86

-$0.10 (-1.23%)

Nov 2, 2026, 10:42 AM ET · Market open

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

-1.23%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

53.7

+18.9 pts

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Sector Rank #206/1028 (Top 20%)

Full Analysis

Key Statistics

Market Data

Market Cap $8.92B

1D Range

7.86 7.90

52W Range

5.71 8.31

Valuation (TTM)

PE 8.17

PB 1.61

EV/EBITDA 14.63

Valuation (NTM)

Forward PE 23.61

Forward PEG 1.25

Price Target $0.00

Cash Flow

FCF Yield 3.0%

SBC Adj. FCF Yield 3.0%

SBC Impact N/A

Margins

Gross Margin 76.7%

Operating Margin 5.1%

FCF Margin 5.0%

Growth (CAGR)

Revenue 3Y | 5Y 4.2% | 4.8%

Dil EPS 3Y | 5Y -4.1% | -6.4%

FCF 3Y | 5Y 27.1% | 11.7%

Returns

ROA 2.7%

ROE 4.8%

ROIC 2.9%

Financial Health

Net Cash

¥40.4B ($248.56M)

Current Ratio 2.24

Interest Coverage 6.87

Dividends

Div Yield 2.77%

Payout Ratio 0.1%

FCF Payout Ratio 106.1%

All Key Statistics

Loading financial charts...

Profile

Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international tr...

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

Employees 10,543

IPO Date Feb 2, 2023

Website www.eisai.com

Fiscal Year n/a

Full Company Profile

Latest News

3 months ago · seekingalpha.com

Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript

4 months ago · reuters.com

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, ‌allowing some patients to begin therapy with injections administered by themselves or a caregiver.